Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · IEX Real-Time Price · USD
271.67
-7.64 (-2.74%)
At close: Jul 2, 2024, 4:00 PM
270.33
-1.34 (-0.49%)
After-hours: Jul 2, 2024, 6:49 PM EDT
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for MDGL stock have an average target of 348.17, with a low estimate of 150 and a high estimate of 410. The average target predicts an increase of 28.16% from the current stock price of 271.67.
Analyst Consensus: Buy
* Price targets were last updated on May 10, 2024.
Analyst Ratings
The average analyst rating for MDGL stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 5 | 5 | 5 | 6 |
| Hold | 1 | 0 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 1 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 11 | 12 | 12 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jun 28, 2024 |
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 11, 2024 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $270 → $200 | Hold | Maintains | $270 → $200 | -26.38% | May 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $425 → $390 | Strong Buy | Maintains | $425 → $390 | +43.56% | May 8, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $389 → $382 | Strong Buy | Maintains | $389 → $382 | +40.61% | May 8, 2024 |
Financial Forecast
Revenue This Year
83.92M
Revenue Next Year
371.45M
from 83.92M
Increased by 342.62%
EPS This Year
-28.55
from -19.99
EPS Next Year
-18.18
from -28.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 103.4M | 534.7M | 1.4B | 3.5B | 4.6B |
| Avg | 83.9M | 371.5M | 1.0B | 1.9B | 2.6B |
| Low | 59.9M | 197.7M | 432.0M | 784.4M | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 537.1% | 289.6% | 249.1% | 136.7% |
| Avg | - | 342.6% | 170.6% | 92.3% | 36.5% |
| Low | - | 135.6% | 16.3% | -22.0% | -40.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -20.09 | -6.87 | 17.92 | 122.82 | 166.17 |
| Avg | -28.55 | -18.18 | 2.61 | 38.66 | 66.02 |
| Low | -33.49 | -25.48 | -15.71 | -4.84 | 30.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 4,601.5% | 329.8% |
| Avg | - | - | - | 1,379.9% | 70.8% |
| Low | - | - | - | - | -20.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.